Meningococcal vaccine evolution

Journal of Preventive Medicine and Hygiene

Volumn 53, Issue 3, 2012, Pages 131-135

  Bona, G ^a   Guidi, C ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Meningococcal conjugate vaccines; Meningococcal disease; Neisseria meningitidis

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; GLYCOCONJUGATE; MENINGOCOCCUS VACCINE;

DRUG CONJUGATION; DRUG EFFICACY; FATALITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INCIDENCE; INFECTION RISK; MEMORY; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT RESPONSE;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; HUMANS; INFANT; INFANT WELFARE; INFANT, NEWBORN; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; RISK FACTORS; VACCINATION; VACCINES, CONJUGATE; WORLD HEALTH;

EID: 84868105899     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27:B51-3.
2. Martinez AI, Dominguez A, Oviedo M, et al. Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain). Vaccine 2009;27:3496-8.
3. Lala HM, Mills GD, Barrat K, et al. Meningococcal disease deaths and the frequency of antibiotic administration delays. J Infect 2007;54:551-7. (Pubitemid 46738505)
4. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neis-seria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50(2):184-91.
5. Kirsch EA, Barton RP, Kitchen L, et al. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis 1996;15:967-79. (Pubitemid 26403789)
6. Rosestein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001;344:1378-88.
7. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:853-61.
8. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol. 2004;53:821-32. (Pubitemid 39238387)
9. Bilukha O, Messonnier N, Fischer M. Use of meningococcal vaccines in the United States. Pediatr Infect Dis J 2007;26:371-6. (Pubitemid 46789315)
10. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010;50(Suppl 2):S37-S44.
11. Trotter C, Findlow J, Balmer P, et al. Seroprevalence of bac tericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol 2007;14:863-8.
12. Lingappa JR, Al-Rabeah AM, Hajjeh R, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003;9:665-71. (Pubitemid 36676361)
13. Snape MD, MacLennan JM, Lockhart S, et al. Demonstration of immunologic memory using serogroup C meningococcal glyco-conjugate vaccine. Pediatr Infect Dis J 2009;28:92-7.
14. Harrison LH, Pelton SI, Wilder-Smith A, et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011;29:3363-71.
15. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningo-coccal serogroup C disease in the UK: a success story. Vaccine 2001;20:S58-67. (Pubitemid 32925012)
16. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of menin-gococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43. (Pubitemid 351364476)
17. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005;1:21-30. (Pubitemid 40037626)
18. Booy R, Jelfs J, El Bashir H, et al. Impact of meningo-coccal C conjugate vaccine use in Australia. Med J Aust 2007;186:108-9. (Pubitemid 46322358)
19. Larrauri A, Cano R, Garcia M, et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005;23:4097-100. (Pubitemid 40814584)
20. Marc LaForce F, Ravenscroft N, Djingarey M, et al. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009;27:B13-9.
21. Centers for Disease Control and Prevention (CDC). Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with menin-gococcal conjugate vaccine. MMWR 2007;56:794-5.
22. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y W-135) meningococcal polysaccharide-diphteria conjugate vaccine versus quadrivalent polysaccharide vaccine in two to ten year-old children. Pediatr Infect Dis J 2005;24:57-62. (Pubitemid 40353317)
23. Keyserling H, Papa T, Korany K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005;159:907-13 (Pubitemid 41423328)
24. Rennels M, King J Jr, Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004;23:429-35. (Pubitemid 38621482)
25. Ostergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (Men ACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009;27:161-8
26. Black S, Klein NP, Shah J, et al. Immunogenicity and tolerabil-ity of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010;28:657-63.
27. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococ-cal conjugate vaccines. Vaccine 2009;27:B30-41.
28. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28:86-91.
29. ® among healthy adolescents. Hum Vaccin 2010;6:881-7.
30. Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010;17:537-44.
31. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299:173-84.
32. Center for Disease Control and Prevention (CDC). Licensure of a Meningococcal Conjugate Vaccine (Menveo) and Guidance for use-Advisory Committee on Immunization Practices (ACIP) 2010. MMWR 2010;59:273.
33. Centers for Disease Control and Prevention. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR 2011; 60: 1391-2.
34. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum. Vaccine 2007;3:290-4.
35. Panatto D, Amicizia D, Lai PL, et al. Neisseria meningitidis group B vaccines. Expert Rev Vaccines 2011;10:1337-51.
36. Rappuoli R. Reverse vaccinology, a genoma-based approach to vaccine development. Vaccine 2001;19:2688-91. (Pubitemid 32234290)
37. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010;362:1511-20.
38. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immuno-genicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617-24.
39. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tol-lerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules. A randomized controlled study. JAMA 2012;307:573-82.
40. Chiappini E, Venturini E, Bonsignori F, et al. Serogroup C Neisseria meningitidis invasive infection analysis of the possible vaccination strategies for a mass campaign. Acta Paediatr 2010;99:1609-14.